Morton, WA, Sonne, SC, Lydiard, RB. Lithium side effects in the medically ill. Int J Psychiatry Med
1993; 23: 357–82.
Frost, RE, Messiha, FS. Clinical uses of lithium salts. Brain Res Bull
1983; 11: 219–31.
Carmen, J, Okafor, K, Ike, E. The effects of lithium therapy on leukocytes: a 1-year follow-up study. J Natl Med Assoc
1993; 85: 301–3.
Colton, CW, Manderscheid, RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis
2006; 3: A42.
Manji, HK, Moore, GJ, Chen, G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry
2000; 48: 740–54.
Hicks, D. Lithium induced renal toxicity–a review of the literature. S D J Med
1991; 44: 343–5.
Gitlin, M. Lithium and the kidney: an updated review. Drug Saf
1999; 20: 231–43.
Bocchetta, A, Loviselli, A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemol Ment Health
2006; 2: 23.
Weintraub, M, Hes, JP, Rotmensch, HH, Soferman, G, Liron, M. Extreme sinus bradycardia associated with lithium therapy. Isr J Med Sci
1983; 19: 353–5.
Montalescot, G, Levy, Y, Hatt, PY. Serious sinus node dysfunction caused by therapeutic doses of lithium. Int J Cardiol
1984; 5: 94–6.
Wolf, ME, Ranade, V, Molnar, J, Somberg, J, Mosnaim, AD. Hypercalcemia, arrhythmia, and mood stabilizers. J Clin Psychopharmacol
2000; 20: 260–4.
Norton, B, Whalley, LJ. Mortality of a lithium-treated population. Br J Psychiatry
1984; 145: 277–82.
Coppen, A, Standish-Barry, H, Bailey, J, Houston, G, Silcocks, P, Hermon, C. Does lithium reduce the mortality of recurrent mood disorders?
J Affect Disord
1991; 23: 1–7.
Vestergaard, P, Aagaard, J. Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord
1991; 21: 33–8.
Muller-Oerlinghausen, B, Ahrens, B, Grof, E, Grof, P, Lenz, G, Schou, M, et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand
1992; 86: 218–22.
Ahrens, B, Muller-Oerlinghausen, B, Schou, M, Wolf, T, Alda, M, Grof, E, et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord
1995; 33: 67–75.
Nilsson, A. Mortality in recurrent mood disorders during periods on and off lithium. A complete population study in 362 patients. Pharmacopsychiatry
1995; 28: 8–13.
Brodersen, A, Licht, RW, Vestergaard, P, Olesen, AV, Mortensen, PB. Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry
2000; 176: 429–33.
Angst, F, Stassen, HH, Clayton, PJ, Angst, J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord
2002; 68: 167–81.
Cipriani, A, Pretty, H, Hawton, K, Geddes, JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry
2005; 162: 1805–19.
Kilbourne, AM, Morden, NE, Austin, K, Ilgen, M, McCarthy, JF, Dalack, G, et al. Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry
2009; 31: 555–63.
Harris, EC, Barraclough, B. Excess mortality of mental disorder. Br J Psychiatry
1998; 173: 11–53.
Miller, BJ, Paschall, CB 3rd, Svendsen, DP. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv
2006; 57: 1482–7.
Zivin, K, Ilgen, MA, Pfeiffer, PN, Welsh, DE, McCarthy, J, Valenstein, M, et al. Early mortality and years of potential life lost among veterans affairs patients with depression. Psychiatr Serv
2012; 63: 823–6.
Young, AH, Hammond, JM. Lithium in mood disorders: increasing evidence base, declining use?
Br J Psychiatry
2007; 191: 474–6.
Blanco, C, Laje, G, Olfson, M, Marcus, SC, Pincus, HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry
2002; 159: 1005–10.
Wolfsperger, M, Greil, W, Rossler, W, Grohmann, R. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J Affect Disord
2007; 99: 9–17.
Shulman, KI, Rochon, P, Sykora, K, Anderson, G, Mamdani, M, Bronskill, S, et al. Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence. BMJ
2003; 326: 960–1.
Blow, FC, Valenstein, M, Austin, K, Khanuja, K, McCarthy, JF. Specialty Care for Veterans with Depression in the VHA: 2002 National Depression Registry Report. VA National Serious Mental Illness Treatment Research & Evaluation Center (SMITREC), VHA Health Services Research & Development, 2003.
Ray, WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol
2003; 158: 915–20.
Hernan, MA, Robins, JM. Authors' response, part I: observational studies analyzed like randomized experiments: best of both worlds. Epidemiology
2008; 19: 789–92.
Cooper, WO, Habel, LA, Sox, CM, Chan, KA, Arbogast, PG, Cheetham, TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med
2011; 365: 1896–904.
Cowper, DC, Kubal, JD, Maynard, C, Hynes, DM. A primer and comparative review of major US mortality databases. Ann Epidemiol
2002; 12: 462–8.
Schneeweiss, S, Rassen, JA, Glynn, RJ, Avorn, J, Mogun, H, Brookhart, MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology
2009; 20: 512–22.
Patorno, E, Bohn, RL, Wahl, PM, Avorn, J, Patrick, AR, Liu, J, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA
2010; 303: 1401–9.
Wyss, R, Girman, CJ, Locasale, RJ, Alan Brookhart, M, Sturmer, T. Variable selection for propensity score models when estimating treatment effects on multiple outcomes: a simulation study. Pharmacoepidemiol Drug Saf
2013; 22: 77–85.
Selim, AJ, Berlowitz, DR, Fincke, G, Rosen, AK, Ren, XS, Christiansen, CL, et al. Risk-adjusted mortality rates as a potential outcome indicator for outpatient quality assessments. Med Care
2002; 40: 237–45.
Brookhart, MA, Schneeweiss, S, Rothman, KJ, Glynn, RJ, Avorn, J, Sturmer, T. Variable selection for propensity score models. Am J Epidemiol
2006; 163: 1149–56.
Patrick, AR, Schneeweiss, S, Brookhart, MA, Glynn, RJ, Rothman, KJ, Avorn, J, et al. The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf
2011; 20: 551–9.
Pearl, J. Invited commentary: understanding bias amplification. Am J Epidemiol
2011; 174: 1223–7.
Brooks, JM, Ohsfeldt, RL. Squeezing the balloon: propensity scores and unmeasured covariate balance. Health Serv Res
2013; 48: 1487–507.
Austin, PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J
2009; 51: 171–84.
Faries, DE, Leon, AC, Haro, JM, Obenchain, RL, Institute, SAS. Analysis of Observational Health Care Data using SAS. SAS Institute, 2010.
Austin, PC, Grootendorst, P, Anderson, GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med
2007; 26: 734–53.
Muller-Oerlinghausen, B, Wolf, T, Ahrens, B, Glaenz, T, Schou, M, Grof, E, et al. Mortality of patients who dropped out from regular lithium prophylaxis: a collaborative study by the International Group for the Study of Lithium-treated patients (IGSLI). Acta Psychiatr Scand
1996; 94: 344–7.
Bocchetta, A. Mortality follow-up of patients since commencing lithium therapy. J Clin Psychopharmacol
2005; 25: 197–9.
Christodoulou, GN, Lykouras, EP. Abrupt lithium discontinuation in manic-depressive patients. Acta Psychiatr Scand
1982; 65: 310–4.
Suppes, T, Baldessarini, RJ, Faedda, GL, Tohen, M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry
1991; 48: 1082–8.
Faedda, GL, Tondo, L, Baldessarini, RJ, Suppes, T, Tohen, M. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry
1993; 50: 448–55
Goodwin, GM. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry
1994; 164: 149–52.
Scott, J, Pope, M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry
2002; 63: 384–90.
Svarstad, BL, Shireman, TI, Sweeney, JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv
2001; 52: 805–11.
Schumann, C, Lenz, G, Berghofer, A, Muller-Oerlinghausen, B. Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Res
1999; 89: 247–57.
Maarbjerg, K, Aagaard, J, Vestergaard, P. Adherence to lithium prophylaxis: I. Clinical predictors and patient's reasons for nonadherence. Pharmacopsychiatry
1988; 21: 121–5.
Aagaard, J, Vestergaard, P. Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Disord
1990; 18: 259–66.
Johnson, RE, McFarland, BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry
1996; 153: 993–1000.
Kessing, LV, Sondergard, L, Kvist, K, Andersen, PK. Adherence to lithium in naturalistic settings: results from a nationwide pharmacoepidemiological study. Bipolar Disord
2007; 9: 730–6.
Lolich, M, Vazquez, GH, Alvarez, LM, Tamayo, JM. Psychosocial interventions in bipolar disorder: a review. Actas Esp Psiquiatr
2012; 40: 84–92.
Colom, F, Vieta, E, Sanchez-Moreno, J, Palomino-Otiniano, R, Reinares, M, Goikolea, JM, et al. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry
2009; 194: 260–5.
Kessing, LV, Hansen, HV, Hvenegaard, A, Christensen, EM, Dam, H, Gluud, C, et al. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry
2013; 202: 212–9.
Goodwin, GM. Evidence-based guidelines for treating bipolar disorder: revised second edition–recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxf)
2009; 23: 346–88.
Chao, SH, Urbano, FL. Introduction: Medicare Section 1013 and AHRQ's Effective Health Care Program. J Manag Care Pharm
2007; 13 (suppl 1): S3–6.
Kales, HC, Valenstein, M, Kim, HM, McCarthy, JF, Ganoczy, D, Cunningham, F, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry
2007; 164: 1568–76.
Schneeweiss, S, Patrick, AR, Solomon, DH, Mehta, J, Dormuth, C, Miller, M, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry
2010; 67: 497–506.
Soyka, M, Apelt, SM, Lieb, M, Wittchen, HU. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. J Clin Psychopharmacol
2006; 26: 657–60.
Wang, PS, Schneeweiss, S, Avorn, J, Fischer, MA, Mogun, H, Solomon, DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med
2005; 353: 2335–41.
Kales, HC, Kim, HM, Zivin, K, Valenstein, M, Seyfried, LS, Chiang, C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry
2012; 169: 71–9.
Baldessarini, RJ, Tondo, L, Davis, P, Pompili, M, Goodwin, FK, Hennen, J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord
2006; 8: 625–39.
Goodwin, FK, Fireman, B, Simon, GE, Hunkeler, EM, Lee, J, Revicki, D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA
2003; 290: 1467–73.
Baldessarini, RJ, Tondo, L, Hennen, J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry
1999; 60 (suppl 2): 77–84.
Ray, WA. Observational studies of drugs and mortality. N Engl J Med
2005; 353: 2319–21.
Manwani, SG, Szilagyi, KA, Zablotsky, B, Hennen, J, Griffin, ML, Weiss, RD. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders. J Clin Psychiatry
2007; 68: 1172–6.
Geddes, JR, Goodwin, GM, Rendell, J, Azorin, JM, Cipriani, A, Ostacher, MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet
2010; 375: 385–95.
Kessing, LV, Hellmund, G, Geddes, JR, Goodwin, GM, Andersen, PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry
2011; 199: 57–63.